Kaleido Biosciences, Inc.
OTC: KLDO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mark A. Wingertzahn
- Employees
- 76
- Headquarters
- Lexington, United States
- IPO year
- 2019
- Market cap
- $4.3K
- Website
- https://kaleido.com
Loading KLDO…
Loading profile data…Frequently asked questions about KLDO
What does Kaleido Biosciences, Inc. (KLDO) do?
Kaleido Biosciences, Inc. is a clinical-stage healthcare firm dedicated to pioneering microbiome metabolic therapies. Its pipeline includes specific drug candidates such as KB195 for urea cycle disorders, KB295 targeting ulcerative colitis, KB174 aimed at hepatic encephalopathy, and KB109 for COVID-19. The company is also advancing programs in o...
Where does KLDO trade?
Kaleido Biosciences, Inc. (KLDO) trades on the Other OTC.
What sector is KLDO in?
Kaleido Biosciences, Inc. (KLDO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Kaleido Biosciences, Inc.?
Mark A. Wingertzahn is the chief executive officer of Kaleido Biosciences, Inc. (KLDO).
Where is Kaleido Biosciences, Inc. headquartered?
Kaleido Biosciences, Inc. is headquartered in United States.
Does KLDO pay a dividend?
Kaleido Biosciences, Inc. (KLDO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KLDO go public?
Kaleido Biosciences, Inc. (KLDO) completed its initial public offering in 2019.